Y-Biologics, Inc. (KOSDAQ:338840)
South Korea · Delayed Price · Currency is KRW 19,790
+100 (0.51%)
At close: Oct 28, 2025
Y-Biologics Company Description
Y-Biologics, Inc., an antibody new drug development platform company, engages in the research and development of immuno-oncology drugs and antibody drugs.
It develops YBL-006, a PD-1 immune checkpoint inhibitor that is in clinical phase 1/2a medication for solid cancers.
The company also develops mono-specific antibodies, such as YBL-011 and YBL-003 for solid cancers; YBL-013, an ALiCE antibody for solid cancers; and YBL-001, an anti-drug conjugate for small cell lung and liver cancers.
Y-Biologics, Inc. was incorporated in 2007 and is headquartered in Daejeon, South Korea.
Y-Biologics, Inc.
| Country | South Korea |
| Founded | 2007 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Young Woo Park |
Contact Details
Address: #715, 17 Techno 4-ro Daejeon South Korea | |
| Website | ybiologics.com |
Stock Details
| Ticker Symbol | 338840 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Young Woo Park | Chief Executive Officer |
| Yeon Kyung Lee | Chief Financial Officer |